Replies to post #108322 on Biotech Values

[DewDiligence]

So how about some arrangement where MNTA agrees to fund a portion of the costs of Phase-3 trials (say 25%) with the partner taking on the rest and the two parties pro-rating the split of any potential revenues accordingly.

This is likely the kind of deal that’s being discussed. I think 25% is close to the upper limit of what MNTA is willing to fund.

M118 needs to complete one or more phase-2b studies before embarking on phase-3, so what we’re talking about is the cumulative development cost for phase-2b and phase-3.

[jbog]

Dew.

In your opinion did you feel the initial phII trial results of M118 were to the level that someone would be interested in taking it forward.

While the results of the EMINENCE trial was successful, I'm not sure whether the degree of success would position M118 with Lovenox or the new drugs coming on line.